These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 12967130)

  • 1. Update on natural killer cells: cross-talk with dendritic cells and role in the cure of acute myeloid leukemias.
    Moretta L; Ferlazzo G; Mingari MC; Melioli G; Moretta A
    Cancer J; 2003; 9(4):232-7. PubMed ID: 12967130
    [No Abstract]   [Full Text] [Related]  

  • 2. Defective killing of dendritic cells by autologous natural killer cells from acute myeloid leukemia patients.
    Fauriat C; Moretta A; Olive D; Costello RT
    Blood; 2005 Sep; 106(6):2186-8. PubMed ID: 15928036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Some studies on natural killer cells in man.
    Lotzová E; McCredie KB; Maroun JA; Dicke KA; Freireich EJ
    Transplant Proc; 1979 Jun; 11(2):1390-2. PubMed ID: 314185
    [No Abstract]   [Full Text] [Related]  

  • 4. Dendritic and natural killer cells cooperate in the control/switch of innate immunity.
    Zitvogel L
    J Exp Med; 2002 Feb; 195(3):F9-14. PubMed ID: 11828015
    [No Abstract]   [Full Text] [Related]  

  • 5. NK cell compartments and their activation by dendritic cells.
    Ferlazzo G; Münz C
    J Immunol; 2004 Feb; 172(3):1333-9. PubMed ID: 14734707
    [No Abstract]   [Full Text] [Related]  

  • 6. Natural killer cells and dendritic cells: rendezvous in abused tissues.
    Moretta A
    Nat Rev Immunol; 2002 Dec; 2(12):957-64. PubMed ID: 12461568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural killer-dendritic cell cross-talk in cancer immunotherapy.
    Kalinski P; Mailliard RB; Giermasz A; Zeh HJ; Basse P; Bartlett DL; Kirkwood JM; Lotze MT; Herberman RB
    Expert Opin Biol Ther; 2005 Oct; 5(10):1303-15. PubMed ID: 16197336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer.
    Arina A; Murillo O; Dubrot J; Azpilikueta A; Alfaro C; Pérez-Gracia JL; Bendandi M; Palencia B; Hervás-Stubbs S; Melero I
    Expert Opin Biol Ther; 2007 May; 7(5):599-615. PubMed ID: 17477799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human leukemia-derived dendritic cells: ex-vivo development of specific antileukemic cytotoxicity.
    Choudhury A; Toubert A; Sutaria S; Charron D; Champlin RE; Claxton DF
    Crit Rev Immunol; 1998; 18(1-2):121-31. PubMed ID: 9419454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions.
    Gerosa F; Gobbi A; Zorzi P; Burg S; Briere F; Carra G; Trinchieri G
    J Immunol; 2005 Jan; 174(2):727-34. PubMed ID: 15634892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effector immune mechanisms in cancer.
    Lotzová E
    Nat Immun Cell Growth Regul; 1985; 4(6):293-304. PubMed ID: 3911064
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of natural killer cells in tumor control--effectors and regulators of adaptive immunity.
    Wallace ME; Smyth MJ
    Springer Semin Immunopathol; 2005 Jun; 27(1):49-64. PubMed ID: 15729567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NK cells interactions with dendritic cells shape innate and adaptive immunity.
    Brilot F; Strowig T; Munz C
    Front Biosci; 2008 May; 13():6443-54. PubMed ID: 18508671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia.
    van den Ancker W; van Luijn MM; Westers TM; Bontkes HJ; Ruben JM; de Gruijl TD; Ossenkoppele GJ; van de Loosdrecht AA
    Immunotherapy; 2010 Jan; 2(1):69-83. PubMed ID: 20635890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated immune responses to infection - cross-talk between human gammadelta T cells and dendritic cells.
    Eberl M; Jomaa H; Hayday AC
    Immunology; 2004 Jul; 112(3):364-8. PubMed ID: 15196203
    [No Abstract]   [Full Text] [Related]  

  • 16. Lysis of fresh leukemic blasts by interferon-activated human natural killer cells.
    Pattengale PK; Sundstrom C; Yu AL; Levine A
    Nat Immun Cell Growth Regul; 1983-1984; 3(4):165-80. PubMed ID: 6597341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunology. A perfect mismatch.
    Kärre K
    Science; 2002 Mar; 295(5562):2029-31. PubMed ID: 11896262
    [No Abstract]   [Full Text] [Related]  

  • 18. Immune status of leukemia patients.
    Kaneko Y; Miyakoshi H; Aoyagi Y; Aoki T
    Haematol Blood Transfus; 1985; 29():200-3. PubMed ID: 3861482
    [No Abstract]   [Full Text] [Related]  

  • 19. Cytotoxicity of cytokine-induced killer cells coated with bispecific antibody against acute myeloid leukemia cells.
    Kaneko T; Fusauch Y; Kakui Y; Okumura K; Mizoguchi H; Oshimi K
    Leuk Lymphoma; 1994 Jul; 14(3-4):219-29. PubMed ID: 7950910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation.
    Dermime S; Mavroudis D; Jiang YZ; Hensel N; Molldrem J; Barrett AJ
    Bone Marrow Transplant; 1997 May; 19(10):989-99. PubMed ID: 9169643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.